A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 09 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 09 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 23 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.